Arvinas

Youtube Subscribe

Open: 47.46 Close: 45.98 Change: -1.48

How to get informed about Arvinas Stock quickly using an AI.

This document will help you to evaluate Arvinas without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Arvinas are: Arvinas, company, Inc, stock, cash, report, price, and the …

Concept Map

Semantic Network

Stock Summary

Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that.

Today's Summary

Arvinas shareholders are still up 143% over 5 years despite pulling back 10% in the past week. Shareholders have received a total shareholder return of 47% over one year. Recent earnings estimate revisions suggest that good things are ahead.

Today's News

Arvinas Inc. reports q4 eps ($2.53), consensus ($1.27) - tipranks.com.com. arvinas inc. arvn stock price. price target cut to $90 from $151 at UBS May. Arvinas shareholders are still up 143% over 5 years despite pulling back 10% in the past week. Shareholders have received a total shareholder return of 47% over one year. Recent earnings estimate revisions suggest that good things are ahead. Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. The company believes its cash, cash equivalents, restricted cash and marketable securities as of December 31, 2023. Arvinas, Inc. (ARVN) Could Rally 42.05%: Heres is How to Trade (Zacks) Wall Street Analysts Predict a 165.07% Upside in the stock. Arvinas, Inc. (NASDAQ:ARVN) insider sells 1,699 shares of stock - defense world. Defense World Staff Posted by Defense World. Citi initiated coverage with a Hold rating on Arvinas Holding Company (NASDAQ: ARVN) on February 14. Based on the companys latest earnings release for the quarter ending September 30, the company reported a quarterly revenue. Sean A. Cassidy Sells 1,702 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock Posted by Defense World Staff on Feb 29th, 2024, 2024. Arvinass Financial Performance Market Capitalization Analysis: The companies market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. Return on Equity (ROE) falls below industry averages, indicating challenges in efficiently using equity capital. Debt-to-equity ratio is below industry norms, indicating a sound financial structure. Arvinas missed estimated earnings by -98.0%, reporting an EPS of $-2.53 versus an estimate of $1.28. The company completed oversubscribed $350 million private placement. Arvinas veritac-2 trial timelines not changed, says oppenheimer - tipranks.com. It lowered the price target to reflect arvinas cash burn guidance. GlobalData tracks drug-specific phase transition and likelihood of approval scores. Arvinass revenue was $78.50 million, a decrease of -40.26% compared to the previous years $131.40 million. Analyst Consensus: Strong Buy Stock Forecasts: Strong buy stock Forecasts. Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

Stock Profile

"Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut."

Keywords

The game is changing. There is a new strategy to evaluate Arvinas fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Arvinas are: Arvinas, company, Inc, stock, cash, report, price, and the most common words in the summary are: arvinas, stock, inc, globenewswire, arvn, new, trial, . One of the sentences in the summary was: Shareholders have received a total shareholder return of 47% over one year. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #arvinas #stock #inc #globenewswire #arvn #new #trial.

Read more →

Youtube Subscribe

---